MUGHEDDU, CRISTINA
 Distribuzione geografica
Continente #
EU - Europa 11.883
NA - Nord America 426
AS - Asia 122
Totale 12.431
Nazione #
IT - Italia 11.783
US - Stati Uniti d'America 422
CN - Cina 77
SE - Svezia 49
SG - Singapore 30
DE - Germania 17
GB - Regno Unito 9
FI - Finlandia 8
VN - Vietnam 8
IE - Irlanda 5
CA - Canada 4
ES - Italia 4
HU - Ungheria 3
HK - Hong Kong 2
IN - India 2
KR - Corea 2
UA - Ucraina 2
FR - Francia 1
JP - Giappone 1
NL - Olanda 1
PT - Portogallo 1
Totale 12.431
Città #
Cagliari 11.758
Fairfield 96
Nyköping 38
Woodbridge 38
Houston 35
Cambridge 27
Seattle 27
Ashburn 24
Wilmington 23
Ann Arbor 15
Beijing 14
Redwood City 13
Shanghai 13
Boston 12
Singapore 12
Boardman 10
Dong Ket 8
Helsinki 8
Jacksonville 6
San Diego 6
Esslingen am Neckar 5
Guangzhou 5
London 5
Mountain View 5
Nanjing 5
Chandler 4
Chengdu 4
Rome 4
Toronto 4
Northvale 3
Wuhan 3
Chicago 2
Dearborn 2
Falkenstein 2
Gijón 2
Gragnano 2
Hangzhou 2
Hong Kong 2
Los Angeles 2
Seoul 2
Szeged 2
Xian 2
Amsterdam 1
Birmingham 1
Brea 1
Dalian 1
Decimomannu 1
Fremont 1
Hebei 1
Henderson 1
Jiaxing 1
Kunming 1
Madrid 1
Menlo Park 1
Munich 1
New Bedfont 1
New York 1
Norwalk 1
Nuremberg 1
Pescara 1
Saint Louis 1
Saint-martin-d'heres 1
San Sperate 1
Santa Clara 1
Selargius 1
Shenyang 1
Shenzhen 1
Valencia 1
Visakhapatnam 1
Waldshut-Tiengen 1
Wandsworth 1
Wuxi 1
Totale 12.282
Nome #
Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy) 1.819
Biologics exposure during pregnancy and breastfeeding in a psoriasis patient 1.298
Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic 1.277
Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic 1.207
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management 1.135
Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab 1.070
Safety of secukinumab treatment in COVID-19 affected psoriatic patients 761
Image Gallery: Green moss-like psoriasis 743
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 711
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 658
The Challenging Differentiation of Psoriatic Arthritis from Other Arthropathies and Nonspecific Arthralgias in Patients with Psoriasis: Results of a Cross-Sectional Rheumatologic Assessment of a Large Dermatologic Cohort 382
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 362
Do not forget about myasthenia gravis when performing botulinum toxin injections 325
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 288
Dermoscopy of Tinea Incognito 212
Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab 168
Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development 76
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 1
Totale 12.493
Categoria #
all - tutte 16.892
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.892


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020615 0 12 8 9 190 137 79 20 17 23 45 75
2020/20214.984 76 163 187 1.791 989 577 301 285 76 217 196 126
2021/20221.265 128 80 86 48 80 151 104 41 82 92 133 240
2022/20232.108 224 237 231 162 214 184 130 124 120 147 171 164
2023/20242.366 122 135 74 112 272 444 223 290 123 163 176 232
2024/20251.110 871 239 0 0 0 0 0 0 0 0 0 0
Totale 12.493